Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae

被引：14

作者：

Millichap, JJ

Pestova, E

Siddiqui, F

Noskin, GA

Peterson, LR

机构：

[1] NW Mem Hosp, Dept Pathol, NW Prevent Epictr, Div Microbiol, Chicago, IL 60611 USA

[2] NW Mem Hosp, Div Infect Dis, Chicago, IL 60611 USA

[3] Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA

[4] Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2001年 / 39卷 / 07期

关键词：

D O I：

10.1128/JCM.39.7.2719-2721.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The association between fluoroquinolone susceptibility and DNA mutations coding for amino acid substitutions in the quinolone resistance-determining region was assessed with 44 clinical isolates of Streptococcus pneumoniae. Twenty-three strains bore at least one amino acid substitution. Only seven strains with mutations were suggested by diminished susceptibility to ciprofloxacin (MTC, greater than or equal to2 pg/ml).

引用

收藏

页码：2719 / 2721

页数：3

相关论文

共 18 条

[1]

[Anonymous], 2000, OV ANT RES

[2] A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus:: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux [J].

Beyer, R ;

Pestova, E ;

Millichap, JJ ;

Stosor, V ;

Noskin, GA ;

Peterson, LR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :798-801

[3] Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae [J].

Brenwald, NP ;

Gill, MJ ;

Wise, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2032-2035

[4] Primary targets of fluoroquinolones in Streptococcus pneumoniae [J].

Fukuda, H ;

Hiramatsu, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :410-412

[5] Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae [J].

Gill, MJ ;

Brenwald, NP ;

Wise, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :187-189

[6] Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro [J].

Heaton, VJ ;

Ambler, JE ;

Fisher, LM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3112-3117

[7] Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci [J].

Jorgensen, JH ;

Weigel, LM ;

Ferraro, MJ ;

Swenson, JM ;

Tenover, FC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :329-334

[8] Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci [J].

Kaneko, A ;

Sasaki, J ;

Shimadzu, M ;

Kanayama, A ;

Saika, T ;

Kobayashi, I .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) :771-775

[9] ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype [J].

Munoz, R ;

DelaCampa, AG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2252-2257

[10]

National Committee for Clinical Laboratory Standards, 2000, M7A5 NCCLS